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Abstract
Background: An endotoxin insult mimics a severe peripheral infection and recent evidence
suggests that a single exposure can cause long-term cognitive deficits. A peripheral injection of LPS
results in production of pro-inflammatory cytokines, such as IL-1β and TNF-α, in the brain and
periphery and these cytokines mediate many effects of the acute phase response including
activation of the HPA axis. The chemokine MCP-1 is highly expressed during endotoxemia and
although much is known about the importance of MCP-1 in peripheral inflammatory responses to
LPS, information about MCP-1 and CNS responses to peripheral LPS is lacking.
Methods: C57Bl/6 mice were administered LPS by intraperitoneal (i.p.) injection, serum and brains
were collected at several time points, and the time course of MCP-1 protein up-regulation was
measured. To examine the role of MCP-1 in activation of the brain during acute systemic
inflammation, we injected MCP-1 knockout (MCP-1-/-) or control C57Bl/6 (MCP-1+/+) mice with
LPS i.p. and measured the levels of selected cytokines and chemokines in serum and brain extracts
6 hours later. Activated microglia were examined by CD45 immunohistochemistry, and serum
corticosterone and ACTH levels were measured by enzyme immunoassay.
Results: We report that LPS injection induces a robust increase in MCP-1 protein levels in serum
and brain, with peak brain levels reached at 6 hrs after LPS administration. MCP-1-/- mice injected
with LPS showed higher levels of serum IL-1β and TNF-α compared to LPS-treated MCP-1+/+ mice.
In contrast, these MCP-1-/- mice showed significantly lower inductions of brain pro-inflammatory
cytokines and chemokines, fewer activated microglia, and a reduction in serum corticosterone
levels.
Conclusion:  MCP-1-/- mice have decreased brain inflammation after a peripheral LPS insult,
despite an exaggerated peripheral response. These data demonstrate an important role for MCP-
1 in regulation of brain inflammation after peripheral endotoxemia.
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Background
The mammalian body responds rapidly to an infection
from invading pathogens by activation of the innate
immune system. Bi-directional communication between
the immune system and the brain is necessary for activa-
tion of the acute phase response and efficient clearance of
the invading organism. Through incompletely under-
stood mechanisms and pathways, the cells of the brain
become activated and turn on specific neural pathways
that regulate the acute phase response whose manifesta-
tions include fever, sickness behaviors, and activation of
the hypothalamic-pituitary-adrenal (HPA) axis. Fever and
sickness behaviors such as lethargy, anorexia, anhedonia,
and social isolation together represent evolutionary adap-
tations to help the organism fight the invading pathogen
[1,2]. Likewise, activation of the HPA axis and subsequent
production of glucocorticoids are critical to the organ-
ism's survival by regulating the body's immune system
responses [3-5].
The endotoxin lipopolysaccharide (LPS) is found in the
outer cell wall of Gram-negative bacteria and when
injected systemically can generate many features of the
acute phase response [2,4] and has therefore been used
extensively as a model for peripherally induced inflamma-
tion. Systemic LPS causes an increase in production of
pro-inflammatory cytokines, such as interleukin (IL)-1β,
tumor necrosis factor (TNF)-α, and IL-6, in the periphery
by immune cells such as monocytes and tissue macro-
phages [6]. These peripherally produced cytokines may
transfer an inflammatory signal to the brain in several
ways: activation in areas of the brain with a leaky blood
brain barrier (BBB), direct transport of cytokines across
the BBB, or a neural route [6]. Certain cells of the brain
express the receptor for LPS, toll like receptor 4 [7], and
these cells may be directly activated by LPS. Further,
migration of blood leukocytes into the central nervous
system (CNS) [8] may also contribute to brain activation.
These peripheral inflammatory signals stimulate certain
brain cells to endogenously express the same pro-inflam-
matory cytokines [2,9-11]. Evidence that innate immune
cells of the brain can be activated by these cytokines is
demonstrated by the observation that a single injection of
IL-1β or TNF-α into selected regions of the brain results in
sickness behaviors or activation of the HPA axis, and
receptors for these cytokines are expressed in several brain
regions [2,12].
A number of chemotactic cytokines or chemokines are
also upregulated in the periphery and brain after a periph-
eral injection of LPS [13-17]. Chemokines are essential in
cell recruitment and trafficking during inflammation, are
involved in regulating leukocyte movement into the CNS
during pathology, and may also affect the BBB permeabil-
ity [18-20]. The chemokine monocyte chemoattractant
protein-1 (MCP-1; also called CCL2) plays an essential
role in several peripheral and CNS inflammatory disor-
ders characterized by mononuclear cell infiltrates, and
inhibiting MCP-1 in mouse models of atherosclerosis,
stroke and experimental autoimmune encephalomyelitis
resulted in a decrease in inflammatory cell recruitment
and reduced disease severity [21-23]. Similarly, there is
decreased myeloperoxidase activity and attenuated liver
and lung injury when MCP-1 is inhibited after cecal liga-
tion and puncture or after systemic LPS challenge [24,25].
However, prior studies [15,26-28] have also shown that
inhibition of MCP-1 activity using neutralizing antibodies
or in knock-out mice lacking MCP-1 resulted in a dysreg-
ulation of the cytokine balance and increased mortality in
models of sepsis induced by cecal ligation and puncture or
LPS, and Salmonella infection. Additional evidence for a
protective or reparative role of MCP-1 includes the obser-
vations that pre-treatment of mice with recombinant
MCP-1 led to a reduction in mortality and pro-inflamma-
tory cytokine induction after a high dose of LPS [15], and
that treatment of an astrocyte cell line with MCP-1 led to
the induction of the neurotrophic factor, basic fibroblast
growth factor [29]. Thus, MCP-1 may play several vital
roles besides one in cell recruitment and may have either
a protective or detrimental role depending on the inflam-
matory stimulus, cell type, or disease state.
Although much is known about the importance of MCP-
1 in peripheral inflammatory responses to LPS, there is lit-
tle information about MCP-1 and CNS responses to
peripheral LPS. The aim of this study, therefore, was to
examine the role of the chemokine MCP-1 in activation of
the brain during acute systemic inflammation. To do this,
we examined the effects of inhibiting MCP-1 on brain
inflammation by using a MCP-1 knock-out (MCP-1-/-)
mouse [30]. Interestingly, we discovered that although the
cytokine response was significantly greater in the serum of
LPS-treated MCP-1-/- mice compared to LPS-treated wild-
type MCP-1+/+ mice, there was a hyporesponse of the
immune cells in the brain of the knockout mice. Specifi-
cally, in the hippocampus and cortex of the LPS-injected
MCP-1-/- mice, there was a decrease in microglia activation
as measured by CD45 immunoreactivity and a decrease in
cytokine and chemokine levels. This decrease in microglia
activation was accompanied by a reduction in serum cor-
ticosterone levels. These data suggest that MCP-1 plays a
critical role either directly or indirectly in activating the
brain during systemic endotoxemia.
Methods
Animals
Female C57Bl/6 (MCP-1+/+) mice were purchased from
Harlan (Indianapolis, IN). MCP-1-/- mice were kindly pro-
vided by Dr. Barrett J. Rollins (Dana Farber Cancer Insti-
tute, Boston, MA) and have been backcrossed eight timesJournal of Neuroinflammation 2008, 5:35 http://www.jneuroinflammation.com/content/5/1/35
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on the C57Bl/6 background [30]. All mice were main-
tained in a pathogen-free facility (the Center for Compar-
ative Medicine) at Northwestern University, and had
access ad libitum to standard laboratory chow and water.
All animal procedures were approved by the Northwest-
ern Animal Care and Use Committee.
MCP-1 time course experiments
Adult female MCP-1+/+  mice (20–25 g) were injected
intraperitoneally (i.p.) with 5 mg/kg LPS (Salmonella typh-
imurium; Sigma, St. Louis, MO). Control mice received an
equivalent volume of saline i.p. The dose of LPS was cho-
sen for the time course experiments so that MCP-1 meas-
urements could be made at longer time points (18 hr and
24 hr) without any mortality. At various times after LPS,
mice were anesthetized with pentobarbital (50 mg/kg)
and blood was drawn by intracardiac puncture, allowed to
clot and centrifuged for serum preparation. Mice were per-
fused with a HEPES buffer (10 mM, pH 7.2) containing a
protease inhibitor mixture (1 μg/ml leupeptin, 100 μM
sodium orthovanadate, 1 mM phenylmethylsulpho-
nylfluoride, 1 μg/ml pepstatin, 1 μg/ml aprotinin), brains
were removed and hippocampus, entorhinal cortex, and
frontal cortex were dissected out. Brain homogenates were
prepared by Dounce homogenization in the HEPES buffer
containing 0.1% Triton-X 100 and the protease inhibitor
mixture. Homogenates were sonicated for 10 seconds on
ice, centrifuged at 10,000 × g for 20 minutes, supernatants
were collected, and protein levels were determined using
the BCA protein assay reagent kit (Pierce, Milwaukee, WI).
Serum levels of MCP-1 were measured using a duo-set
ELISA (R&D Systems, Minneapolis, MN) per the manufac-
turer's instructions, and MCP-1 levels in brain superna-
tants were measured using a multiplex assay per the
manufacturer's instructions (Meso-Scale Discovery
(MSD), Gaithersburg, MD).
MCP-1-/- and MCP-1+/+ experiments
Mice were injected i.p. with 10 mg/kg LPS. Control mice
received an equivalent volume of saline i.p. At 6 hours
after LPS or saline treatment, mice were anesthetized and
blood and brains collected and dissected as described
above. Serum IL-1β and TNF-α levels were measured
using a duo-set ELISA (R&D Systems), and IL-1β and TNF-
α levels in brain supernatants were measured using a mul-
tiplex assay per the manufacturer's instructions (MSD,
Gaithersburg, MD).
Brain multi-analyte profile
Entorhinal cortex supernatants were analyzed in a multi-
analyte profile (Rodent MAP™ Antigens, Version 1.6) by
Rules-Based Medicine, Austin, TX. The least detectable
dose (LDD) was determined as the mean + 3 standard
deviations of 20 blank readings. The LDDs for each of the
analytes are: eotaxin (2.5 pg/ml), MCP-3 (6.3 pg/ml),
MIP-1α (45 pg/ml), MIP-1β (16 pg/ml), MIP-1γ (15 pg/
ml), MIP-3β (93 pg/ml).
Serum corticosterone and ACTH EIA
Mice were injected with LPS (10 mg/kg) or saline i.p.
between 0830 and 1100 h and sacrificed 6 hours later.
Levels of serum corticosterone were measured using an
EIA kit per the manufacturer's instructions (Assay Designs,
Ann Arbor, MI). The assay sensitivity was 27.0 pg/ml. Lev-
els of serum ACTH were measured using an EIA kit per the
manufacturer's instructions (Bachem, Torrance, CA). The
minimal detectable ACTH concentration was 0.04 ng/ml.
Histology and immunostaining
After perfusion and dissection, one hemibrain of each
mouse was fixed in 4% paraformaldehyde/PBS and cryo-
preserved in 30% sucrose/PBS containing 0.02% sodium
azide. Brains were sectioned coronally on a freezing
microtome at 30 μm. Every 24th section was collected in
0.1 M phosphate buffer, pH 7.6 and these free-floating
sections were then incubated overnight at room tempera-
ture with rat anti-CD45 antibody (1:2000; Serotec). After
washes, the sections were incubated with secondary bioti-
nylated goat anti-rat IgG (Jackson ImmunoLabs) at
1:2000 for 2 h at room temperature. The Vector Laborato-
ries (Burlingame, CA) ABC kit was used with DAB as chro-
mogen to visualize the reaction product. The sections
were then mounted on charged slides, dehydrated in a
series of alcohols, cleared in xylene, and coverslipped. The
slides were then coded and 10–15 random pictures were
taken by a blinded observer using the Fractionator Probe
in the Stereo Investigator 7 program (MBF Bioscience,
Williston, VT) from at least 2 sections of hippocampus
and cortex from each mouse brain. This approach was
used to capture unbiased images throughout the cortex
and hippocampus. NIH Image J software was used to
measure the intensity of CD45 immunoreactivity in the
hippocampus and cortex. The random images were con-
verted to a grayscale 8-bit picture using Image J, and the
grayscale image was then converted to a binary mode
(black and white) and the mean density for all pixels in
the chosen field was calculated. Grayscale values below
the cut-off (CD45 immunoreactivity) become black and
those above become white. The mean density readout is a
number between 0 (pure black) and 255 (pure white),
and was subsequently converted to a scale between 0
(pure white) and 100 (pure black). The mean pixel densi-
ties of at least 7 pictures per brain region were averaged
per mouse.
Statistical analyses
Experimental and control groups were compared using
one-way ANOVA with the Newman-Keuls post hoc analysis
using a statistical software package (GraphPad Prism, ver-Journal of Neuroinflammation 2008, 5:35 http://www.jneuroinflammation.com/content/5/1/35
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sion 4.0; GraphPad Software, San Diego, CA). Statistical
significance was assumed when p < 0.05.
Results
Time course of MCP-1 protein expression in serum and 
brain
To define the time course of MCP-1 protein production in
response to a peripheral injection of LPS, we measured
MCP-1 levels in the serum and in brain frontal cortex at
various time points after i.p. administration of LPS to
C57Bl/6 mice. The levels of MCP-1 in the serum showed
a robust, significant increase by 1.5 hours, and remained
significantly elevated over controls through 24 hours (Fig.
1A). In the brain, MCP-1 levels were significantly upregu-
lated by 3 hours, peaked at 6 hours, and slowly waned to
a lower but still significantly elevated level at 24 hrs (Fig.
1B). Specifically, by 3 hours, the brain MCP-1 production
was at 47% of the maximum level seen at 6 hours, and at
24 hours was still at 61% of the maximum (Fig. 1B). Due
to the limited number of MCP-1-/- mice available, in all
subsequent experiments we used a single time point of 6
hours. Six hours after LPS treatment represents a point of
robust production of MCP-1 protein in the brain and at
this time point we were also able to measure significant
levels of the cytokines IL-1β and TNF-α in both the brain
and serum (data not shown).
Inhibition of MCP-1 increases peripheral pro-
inflammatory cytokine production
Previous studies have demonstrated a critical role for the
pro-inflammatory cytokines IL-1β and TNF-α in disease
pathogenesis during endotoxemia [31,32]. We performed
experiments to determine whether MCP-1 regulates the
production of these pro-inflammatory mediators during
treatment with LPS. To do this, MCP-1-/- mice or wild-type
MCP-1+/+ mice were injected i.p. with LPS or saline, and
serum was obtained 6 hours later. As shown in Fig. 2A,
treatment with LPS significantly increased IL-1β protein
levels above saline controls in both the MCP-1+/+ and
MCP-1-/- mice, but the LPS-injected MCP-1-/- mice showed
a 2.4 fold increase in IL-1β protein above that seen in the
LPS-injected MCP-1+/+ mice. Similar to IL-1β, serum TNF-
α was also significantly increased in LPS-injected mice
compared to saline controls, with the LPS-injected MCP-
1-/- mice showing a 1.5 fold higher increase in TNF-α com-
pared to MCP-1+/+ mice (Fig. 2B). These data confirm
prior studies from our lab [27] and others [15] that found
an increase in TNF-α in serum of MCP-1 deficient mice
challenged with LPS.
Inhibition of MCP-1 decreases brain inflammation
Stimulation of the brain and neural pathways is essential
for activation of the HPA axis, activation of sickness
behaviors, and regulation of the peripheral immune sys-
tem. To examine the role of MCP-1 in activating the brain
during endotoxemia, we quantified the amount of brain
inflammation by first measuring production of the pro-
inflammatory cytokines IL-1β and TNF-α in three brain
regions. MCP-1-/- or MCP-1+/+ mice were injected i.p. with
LPS or saline, brains were harvested and dissected 6 hours
later, and IL-1β and TNF-α levels in entorhinal cortex,
frontal cortex, and hippocampal supernatants were meas-
ured. These brain regions were selected because the hip-
pocampus and cortex are areas affected by
neuroinflammation in chronic neurodegenerative disor-
ders such as Alzheimer's disease. As expected, LPS treat-
ment induced an increase in the levels of IL-1β and TNF-
α in all brain regions compared to saline-treated mice
(Fig. 3). However, unexpectedly we found that the IL-1β
and TNF-α response to LPS was lower in all brain regions
in the MCP-1-/- mice compared to the MCP-1+/+ mice (Fig.
3). Specifically, the IL-1β protein levels in the entorhinal
cortex, frontal cortex, and hippocampus of the LPS-
injected MCP-1-/- mice were 32.9%, 37.7%, and 53.9% of
the respective LPS-injected MCP-1+/+ mice (Fig. 3A). There
was an even more striking reduction in the TNF-α protein
levels in the LPS-injected MCP-1-/-  mice, where the
entorhinal cortex, frontal cortex, and hippocampus levels
were 12.5%, 11.5%, and 17.4% of the respective levels
from the LPS-injected MCP-1+/+ mice (Fig. 3B). Similar
results for IL-1β and TNF-α were found in the cerebellum
(data not shown). The anti-inflammatory cytokine IL-10,
although significantly upregulated with LPS treatment,
was not changed between the LPS-treated MCP-1-/- mice
and LPS-treated MCP-1+/+ mice (data not shown).
Microglial cells and perivascular and meningeal macro-
phages are the main sources of IL-1β in the brain after
peripheral LPS injections [2]. Since there was a decrease in
IL-1β and TNF-α in the brains of the MCP-1-/- mice, we
investigated whether this corresponded to a decrease in
activated microglia in these mice. To examine whether
there was a decrease in activation of these immune cells,
we performed CD45 immunohistochemistry on the hip-
pocampal and cortical sections of saline- or LPS-injected
MCP-1-/- or MCP-1+/+ mice. As shown in Fig. 4A, B, micro-
glia in the saline-injected mice appear phenotypically to
be in the classic resting state. After LPS injection, the
mouse brains show more intense staining and a pheno-
type consistent with activated microglia: enlarged and de-
ramified cell bodies. Quantification of the CD45 immu-
noreactivity showed that peripheral LPS injection resulted
in a significant increase in CD45 immunoreactivity over
saline-injected controls at 6 hours (Fig. 4C, D). In addi-
tion, there is a significantly lower amount of CD45 immu-
noreactivity in both the hippocampus and cortex of the
LPS-injected MCP-1-/-  mice compared to LPS-injected
MCP-1+/+  mice (Fig. 4C, D). We also observed fewer
stained cells resembling leukocytes in and surrounding
the hippocampus of the LPS-injected MCP-1-/- mice (1 ofJournal of Neuroinflammation 2008, 5:35 http://www.jneuroinflammation.com/content/5/1/35
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MCP-1 is increased in a time-dependent manner in serum and brain after LPS treatment Figure 1
MCP-1 is increased in a time-dependent manner in serum and brain after LPS treatment. C57Bl/6 mice were 
injected i.p. with LPS, and serum and brain frontal cortex were collected at 1.5, 3, 6, 9, 12, 18, and 24 hours after LPS treat-
ment. The 0 hr time point represents saline-injected controls. MCP-1 protein levels were measured in serum (A) and brain (B) 
as described in Methods. Values are represented as mean ± SEM of duplicate determinations per sample and are pooled from 
two independent experiments, n = 2–9 mice per time point. * represents significant difference from 0 hr control, p < 0.05.Journal of Neuroinflammation 2008, 5:35 http://www.jneuroinflammation.com/content/5/1/35
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Pro-inflammatory cytokines IL-1β and TNF-α are increased in serum from MCP-1-/- mice after LPS treatment Figure 2
Pro-inflammatory cytokines IL-1β and TNF-α are increased in serum from MCP-1-/- mice after LPS treatment. 
MCP-1+/+ or MCP-1-/- mice were injected i.p. with LPS or saline, and serum was collected 6 hours later. IL-1β (A) and TNF-α 
(B) levels were measured by ELISA as described in Methods. Values are represented as mean ± SEM of duplicate determina-
tions and are pooled from two independent experiments, n = 5–11 mice per group. LPS-injected MCP-1+/+ mice mean value is 
577.6 pg/ml (IL-1β) and 573.4 pg/ml (TNF-α). ** represents significant difference between LPS-treated MCP-1+/+ mice and LPS-
treated MCP-1-/- mice, p < 0.001; # represents significant difference between saline-treated MCP-1+/+ mice and LPS-treated 
MCP-1+/+ mice, p < 0.05; and ≠ represents significant difference between saline-treated MCP-1-/- mice and LPS-treated MCP-1-/
- mice, p < 0.001.Journal of Neuroinflammation 2008, 5:35 http://www.jneuroinflammation.com/content/5/1/35
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4 mice) compared to LPS-injected MCP-1+/+ mice (4 of 5
mice) (e.g. see arrow in Fig. 4A for examples). These data
suggest that there was a decrease in activation and number
of immune cells in the brains of the LPS-injected MCP-1-/
- mice compared to LPS-injected MCP-1+/+ mice.
High doses of peripheral LPS injections cause increases in
many pro-inflammatory mediators in the brain, including
chemokines. Based on our observations of a decrease in
microglia activation in the brains of the LPS-injected
MCP-1-/- mice, we examined if other chemokine proteins
were also reduced. Because previous data demonstrated
that the brain cytokine levels in saline-injected mice were
low or below detection limits, we used only saline-
injected MCP-1+/+ mice and compared the LPS-induced
levels of several chemokines in the MCP-1-/- and MCP-1+/
+ mice. As shown in Fig. 5A–E, MIP-1α (CCL3), MIP-1β
(CCL4), MIP-1γ (CCL9), MCP-3 (CCL7), and eotaxin
(CCL11) proteins were all increased with LPS treatment,
but were significantly decreased in the LPS-treated MCP-1-
/- mice compared with LPS-treated MCP-1+/+ mice. This
reduced response to LPS appeared to be relatively selective
to only certain chemokines as there was no difference in
MIP-3β (CCL19) protein levels between the LPS-treated
MCP-1-/- mice and LPS-treated MCP-1+/+ mice (Fig. 5F). A
variety of other analytes measured in the entorhinal cortex
supernatants (data not shown) were either increased in
the LPS-treated MCP-1-/- mice (IL-3, IL-4, IL-12p70, mye-
loperoxidase), or not significantly different between the
LPS-treated MCP-1-/- mice and the LPS-treated MCP-1+/+
mice (CD40, M-CSF, IL-2, IL-10), further demonstrating
selectivity of the response of the MCP-1-/- mice. Alto-
gether, these data show that the inhibition of MCP-1
results in a decrease in several inflammatory cytokines
and chemokines in the brain and a decreased activation of
microglia after peripheral LPS administration.
Inhibition of MCP-1 is associated with decreased serum 
corticosterone levels
In the brain, the pro-inflammatory cytokines IL-1β and
TNF-α have been linked to activation of the HPA axis
[4,12]. Since we found decreased inflammation and
Pro-inflammatory cytokines IL-1β and TNF-α are decreased in brains of MCP-1-/- mice after LPS treatment Figure 3
Pro-inflammatory cytokines IL-1β and TNF-α are decreased in brains of MCP-1-/- mice after LPS treatment. 
MCP-1+/+ or MCP-1-/- mice were injected i.p. with LPS or saline, and brains were removed and dissected 6 hours later. IL-1β 
(A) and TNF-α(B) levels in entorhinal cortex, frontal cortex, and hippocampus supernatants were measured by MSD as 
described in Methods. Values are represented as mean ± SEM of duplicate determinations and are pooled from two independ-
ent experiments, n = 5–11 mice per group. ** represents significant difference between LPS-treated MCP-1+/+ mice and LPS-
treated MCP-1-/- mice, p < 0.001; # represents significant difference between saline-treated MCP-1+/+ mice and LPS-treated 
MCP-1+/+ mice, p < 0.001; and ≠ represents significant difference between saline-treated MCP-1-/- mice and LPS-treated MCP-1-
/- mice, p < 0.05.Journal of Neuroinflammation 2008, 5:35 http://www.jneuroinflammation.com/content/5/1/35
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cytokine production in brains of the LPS-treated MCP-1-/-
mice, we hypothesized that this hypoactivation might
affect production of glucocorticoids, which is a down-
stream product from activation of the HPA axis. To test
this, we collected serum from MCP-1-/- or MCP-1+/+ mice
injected with LPS or saline after 6 hours, and measured
levels of corticosterone, the primary glucocorticoid
present in mice [12]. As shown in Fig. 6A, corticosterone
levels were increased after LPS treatment, but were signif-
icantly lower in the LPS-injected MCP-1-/- mice compared
to the LPS-injected MCP-1+/+ mice. Corticosterone levels
in the saline-injected MCP-1-/- mice were also somewhat
lower than the saline-injected MCP-1+/+ mice, but this dif-
ference was not significantly different. A decreased pro-
duction of corticosterone in response to LPS may be due
to a primary adrenal insufficiency affecting the adrenal
glands directly or a secondary adrenal insufficiency which
may be caused by a decrease in ACTH, a hormone pro-
duced by the pituitary gland and largely responsible for
stimulating corticosterone [33]. To test this we measured
serum ACTH levels and found that there was a significant
increase after LPS treatment (Fig. 6B). There was also a
Brain CD45 immunoreactivity is reduced in MCP-1-/- mice after LPS treatment Figure 4
Brain CD45 immunoreactivity is reduced in MCP-1-/- mice after LPS treatment. MCP-1-/- and MCP-1+/+ mice were 
injected i.p. with LPS or saline, and brains were removed 6 hours later. Brain sections (30 μm) were stained with anti-CD45 as 
described in Methods. Fields of view were randomly generated using StereoInvestigator for 2–3 sections per mouse and photo-
graphed at 20× magnification using a Nikon Eclipse 80 i microscope. Arrow shows example of morphologically identified leuko-
cytes. Immunoreactive density was measured on at least 7 pictures from both the hippocampus (A) or cortex (B) per mouse 
and analyzed by Image J. Values for the hippocampus (C) and cortex (D) are represented as mean ± SEM, n = 5 mice per group. 
** represents significant difference between LPS-treated MCP-1+/+ mice and LPS-treated MCP-1-/- mice, p < 0.001; # represents 
significant difference between saline-treated MCP-1+/+ mice and LPS-treated MCP-1+/+ mice, p < 0.001; and ≠ represents signif-
icant difference between saline-treated MCP-1-/- mice and LPS-treated MCP-1-/- mice, p < 0.01. Scale bar = 50 μm.Journal of Neuroinflammation 2008, 5:35 http://www.jneuroinflammation.com/content/5/1/35
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decrease in average serum ACTH levels in the LPS-injected
MCP-1-/- mice compared to LPS-injected MCP-1+/+ mice,
although this did not reach significance due to high inter-
individual variability (Fig. 6B). These data suggest that
MCP-1 insufficiency in LPS-treated mice results in
reduced corticosterone production.
Discussion
We report here that MCP-1-/-  mice show a decreased
upregulation of brain cytokine and chemokine produc-
tion and decreased activation of brain immune cells after
systemic LPS treatment compared to wild-type MCP-1+/+
mice. These decreased responses were correlated with
lower serum corticosterone levels in the knockout mice.
In contrast, there were significantly higher levels of the
pro-inflammatory cytokines IL-1β and TNF-α in the
serum of LPS-injected MCP-1-/- mice compared to LPS-
injected MCP-1+/+ mice. These data suggest that during
endotoxemia MCP-1 is necessary for full activation of the
brain immune cells and production of endogenous brain
inflammatory mediators. Further, the lower levels of cor-
ticosterone, a potent immunosuppressant, in the serum of
MCP-1-/- mice may be one factor involved in the increased
immune response in the periphery in these mice.
The mechanistic relationship between MCP-1 and the
production of peripheral inflammatory mediators is not
completely understood. Previous studies have shown that
MCP-1 knockout mice or wild type mice treated with
MCP-1 neutralizing antibodies show a reduction in the
serum levels of the anti-inflammatory cytokine IL-10 and
increased levels of the pro-inflammatory cytokine TNF-α
after LPS injection [15,27]. Further, when recombinant
mouse MCP-1 is administered to mice receiving LPS, IL-
10 levels are increased and TNF-α levels are decreased in
the serum [15]. Our data showing increased levels of IL-1β
and TNF-α in the serum of LPS-injected MCP-1-/- mice
compared to wild-type mice are consistent with these pre-
vious studies, and suggest that MCP-1 may be involved in
controlling the balance between production of pro-
inflammatory and anti-inflammatory mediators by
peripheral immune cells.
CC Chemokines are decreased in brains of MCP-1-/- mice after LPS treatment Figure 5
CC Chemokines are decreased in brains of MCP-1-/- mice after LPS treatment. MCP-1-/- and MCP-1+/+ mice were 
injected i.p. with LPS or saline (MCP-1+/+ mice only), and brains were removed and dissected 6 hours later. Entorhinal cortex 
was homogenized and supernatant assayed by Rules-Based Medicine for MIP-1α (A), MIP-1β (B), MIP-1γ (C), MCP-3 (D), 
eotaxin (E), and MIP-3β (F). Values are represented as mean ± SEM, n = 4–6 mice per group. ** or * represents significant dif-
ference between LPS-treated MCP-1+/+ mice and LPS-treated MCP-1-/- mice, **p < 0.001, *p < 0.01; # represents significant dif-
ference between saline-treated MCP-1+/+ mice and LPS-treated MCP-1+/+ mice, p < 0.001.Journal of Neuroinflammation 2008, 5:35 http://www.jneuroinflammation.com/content/5/1/35
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Serum corticosterone levels are reduced in MCP-1-/- mice after LPS treatment Figure 6
Serum corticosterone levels are reduced in MCP-1-/- mice after LPS treatment. MCP-1-/- and MCP-1+/+ mice were 
injected i.p. with LPS or saline, and serum was collected 6 hours later. Corticosterone (A) or ACTH (B) levels were measured 
by EIA as described in Methods. Values are represented as mean ± SEM of singlet determinations and are pooled from two 
independent experiments, n = 4–11 mice per group. * represents significant difference between LPS-treated MCP-1+/+ mice and 
LPS-treated MCP-1-/- mice, p < 0.01; # represents significant difference between saline-treated MCP-1+/+ mice and LPS-treated 
MCP-1+/+ mice, p < 0.001; and ≠ represents significant difference between saline-treated MCP-1-/- mice and LPS-treated MCP-1-
/- mice, p < 0.001.Journal of Neuroinflammation 2008, 5:35 http://www.jneuroinflammation.com/content/5/1/35
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Another mechanism by which MCP-1 may influence
peripheral inflammatory responses is by affecting the pro-
duction of immune regulating glucocorticoids. Glucocor-
ticoids like corticosterone are produced by the adrenal
gland after activation of the HPA axis and exert powerful
anti-inflammatory properties [4]. Glucocorticoids can
both suppress production of inflammatory mediators
such as IL-1β, TNF-α, prostaglandins, free oxygen radicals,
and nitric oxide, and also upregulate expression of anti-
inflammatory cytokines such as IL-10 and TGF-β [3,33].
Further, adrenalectomized mice show increased mortality
and increased plasma levels of IL-1β and TNF-α after LPS
treatment and this mortality can be reversed by treatment
with glucocorticoids [4]. The lower levels of corticoster-
one we detected in the serum of LPS-injected MCP-1-/-
mice may contribute to the increased levels of serum
cytokines seen in these mice, but this idea needs to be fur-
ther tested.
In addition to its effects on peripheral inflammatory
responses, LPS administration can lead to upregulation of
detrimental neuroinflammatory responses. Recent studies
have shown that a single injection of a high dose of LPS (5
mg/kg) causes a decrease in neuronal numbers in the sub-
stantia nigra 10 months after injection and is correlated to
increased microglial activation and TNF-α production
[34]. Other studies have found long-term losses in neu-
rons, cognitive deficits, or decreases in hippocampal size
after peripheral LPS exposure [35,36]. Although a number
of previous studies have examined the relationship
between MCP-1 and inflammatory cytokine production
in the peripheral immune system, less is known about the
role of MCP-1 in CNS inflammation after LPS administra-
tion. Our data showing that a peripheral injection of LPS
induces an increase in brain MCP-1 levels are consistent
with a previous report showing an increase in brain MCP-
1 protein levels at 1 hour after a 3 mg/kg i.p. LPS injection
[37]. In other studies, MCP-1 mRNA was found to be rap-
idly expressed starting at 30 minutes in areas lacking the
BBB and along blood vessels [14], and MCP-1 mRNA
expression appeared throughout the brain parenchyma
starting by 3 hours and peaking at 6–8 hours after sys-
temic LPS administration [13]. Further, in the brain both
immune cells like macrophages/microglia [14] and non-
immune cells like endothelia [14] and astrocytes [13] can
produce MCP-1 after peripheral LPS. These data suggest a
pattern of LPS-induced MCP-1 expression that begins in
the periphery and spreads to the brain, first in areas that
are in contact with peripherally circulating inflammatory
mediators and then throughout other areas of the brain.
Other inflammatory mediators also follow a similar site-
specific pattern of expression after peripheral LPS, includ-
ing cyclooxygenase-2, TNF-α, IL-1β, inducible nitric oxide
synthase and Iκ Bα, where these molecules are first upreg-
ulated in the choroid plexus, circumventricular organs,
and/or near blood vessels [7,38-41].
Whether LPS-induced increases in MCP-1 in brain are
mechanistically coupled to changes in brain inflamma-
tion has not been explored in detail. The results reported
here showing that MCP-1-/- mice have decreased brain
inflammation after systemic LPS administration com-
pared to wild-type mice suggest that MCP-1 has an impor-
tant role in activating the brain during peripheral
endotoxemia. There are several possible mechanisms by
which MCP-1 can regulate neuroinflammation and the
production of inflammatory mediators in the CNS.
First, MCP-1 in the brain may act as a chemoattractant to
recruit microglia or other immune cells to areas of pathol-
ogy or inflammation; once activated near the site of
pathology, the recruited cells can produce more pro-
inflammatory mediators thus increasing inflammation.
This possibility is supported by observations that MCP-1
is chemotactic to microglia in vitro [42], and that injection
of recombinant MCP-1 into the striatum or hippocampus
of mice results in a significant increase in numbers of
microglia/monocytes near the injection site compared to
vehicle-injected mice [43,44]. Other animal models also
support a chemoattractant role for MCP-1. For example,
in rodent stroke models, inhibition of MCP-1 using
knockout mice or anti-MCP-1 gene therapy results in
fewer activated microglia and astrocytes and significantly
smaller infarcts [22,45], while overexpression of MCP-1 is
associated with increased chemoattraction of immune
cells and larger infarct volumes [46]. MCP-1 has also been
implicated in immune cell recruitment in several other
CNS disorders such as demyelinating diseases, lesion
models, and cortical injury [23,47,48]. Our findings of
decreased activation of microglia as measured by CD45
staining in the LPS-treated MCP-1-/- mice that correlates
with a decrease in brain inflammatory cytokines suggest
that MCP-1 is necessary for recruitment and activation of
microglia. Future studies are necessary to further delineate
the detailed mechanisms, such as flow cytometry to quan-
tify cell infiltration into the brain and MCP-1 production.
Second, MCP-1 may be required for glia to mount an
effective neuroinflammatory response, either through
altering the balance between anti-inflammatory and pro-
inflammatory responses towards a more pro-inflamma-
tory profile or in "priming" glial cells toward a more
inflammatory profile in the brain. Our results so far with
the MCP-1-/- mice do not indicate a major increase in anti-
inflammatory mediators in the brain. For example, IL-10
levels were not different in the LPS-injected MCP-1-/- mice
versus the LPS-injected MCP-1+/+ mice. The idea of a MCP-
1 "priming" mechanism driving an inflammatory profile
comes from studies showing that when LPS is injectedJournal of Neuroinflammation 2008, 5:35 http://www.jneuroinflammation.com/content/5/1/35
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directly into the striatum of MCP-1-/- mice, there is a
decrease in inflammatory cytokine production that is not
correlated with activation or recruitment of microglia or
brain immune cells [43]. The authors propose that low
levels of MCP-1 along with other inflammatory mediators
in the brain result in "priming" of the glial cells to become
more responsive to later inflammatory insults, and the
total inhibition of MCP-1 in the knockout model renders
the glia less responsive [43]. We are currently investigating
this possibility with glial cell cultures.
Third, MCP-1 may also be important in regulation of the
BBB, and disruption of this regulation might lead to
increased permeability of the BBB and more leukocyte
infiltration from the periphery. Support for this idea
comes from the finding that MCP-1 can increase the BBB
permeability to FITC-albumin [20] and modulate the
expression of tight junction proteins in endothelial cells
of the BBB [20,49]. It is possible that MCP-1 is involved in
increasing BBB permeability after an LPS insult, thereby
allowing infiltration of immune cells. The lack of MCP-1
in the knockout mice would then result in less brain
inflammation because of fewer infiltrating immune cells.
We have not directly tested this possibility, but have
observed that 4 of 5 MCP-1+/+ mice injected with LPS had
what appeared to be leukocyte infiltration into the brain
parenchyma, whereas only 1 of 4 MCP-1-/- mice showed
these cells. These data indicate that the lack of MCP-1 may
confer a protective effect against alterations in BBB perme-
ability after LPS treatment.
Conclusion
In summary, we find that MCP-1-/- mice have decreased
brain inflammation after a peripheral LPS insult, despite
an exaggerated peripheral response. These data suggest an
important role for MCP-1 in regulation of brain inflam-
mation after peripheral endotoxemia. Although the mech-
anisms of activating the brain after acute peripheral
inflammation are incompletely understood, our data sug-
gest that MCP-1 may be critical in transferring inflamma-
tory signals from the periphery to the brain.
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